or wait 15s
Japan-based JCR Pharmaceuticals Co., a global specialty biopharmaceutical company dedicated to developing
Chinese startup Rona Therapeutics has granted Roche an exclusive worldwide license for Rona's investigational
Nanyang Technological University (NTU), Singapore and global biopharmaceutical company Boehringer Ingelhe
The Abu Dhabi Public Health Centre (ADPHC) has signed a strategic Memorandum of Understanding (MoU) with Ultra
The National Centre for Engineering Biology (NCEB), hosted at the National University of Singapore (NUS),
United Immunity, a clinical stage biotechnology company, has raised a total of ¥2.2 billion in private fin
PurMinds Enterprises, Inc. (formerly Pacific Software, Inc.) has announced the signing of a collaboration agre
Theramex, a London-headquartered specialty pharmaceutical company dedicated to women and their health, and Chi
360biolabs, a BioAgilytix company, has opened a new laboratory in Sydney, bringing its established bioanalytic
GCCL, a South Korea-based leading global clinical trial central laboratory, has signed a Memorandum of Underst
Neurology is moving from a history of high-risk failures to a period of unprecedented therapeutic experimentation. For decades, the complexity of the brain, limited understanding of disease biology and the formidable blood-brain barrier (BBB) made central nervous system (CNS) drug development one of pharma’s toughest challenges. That equation is now beginning to shift.
Advances in neurobiology, neuroimmunology, precision medicine and drug-delivery technologies are opening new routes to diseases once considered largely untreatable. Recent approvals have introduced disease-modifying and genetically targeted therapies, while the Phase III pipeline is testing approaches aimed at Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Dravet syndrome and other neurological disorders.
Behind this momentum is a deeper change: developers are moving beyond managing symptoms towards targeting the biological mechanisms that drive disease. The question now is whether this scientific momentum can finally translate into durable clinical benefit—and make disease modification a repeatable reality in neurology.
For Feedback, please email us at: coo@mmactiv.com
International Nurse Practitioner Conference 2026 - NP Conference
PubScholars
info@pubscholars.org https://nursepractitionerconferences.pubscholars.org/The Sofia Hotel, 150 W Broadway, San Diego, CA 92101, United States
Australia's Biggest Week in Biotech
AusBiotech
communications@ausbiotech.org www.biggestweekinbiotech.orgGold Coast Conference and Exhibition Centre
57th APACPH Conference 2026 – Leveraging Healthcare Technology and Innovation for Public Health Advancement
APACPH
contact@apacph.org https://apacph2026.com/National Cheng Kung University (NCKU).
